((3aR,4R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl 4-methylbenzenesulfonate | CAS:13007-50-6

We serve ((3aR,4R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl 4-methylbenzenesulfonate CAS:13007-50-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
((3aR,4R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl 4-methylbenzenesulfonate

Chemical Name:((3aR,4R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl 4-methylbenzenesulfonate
CAS.NO:13007-50-6
Synonyms:((3aR,4R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl 4-methylbenzenesulfonate
methyl 5-tosyl-5-deoxy-2,3-O-isopropyliden-D-ribofuranoside
1-O-methyl-2,3-O-(1-methylethylidene)-5-O-(4-methylbenzenesulfonyl)-D-ribofuranoside
5-O-p-toluenesulfonyl-2,3-O-isopropylidene-β-D-ribofuranoside
1-O-methyl-2,3-O-(1-methylethylidene)-5-O-(4-methylbenzene sulfonyl)-D-ribofuranoside
methyl 5-(4-methylbenzenesulfonate)-2,3-O-(1-methylethylidene)-D-ribofuranoside
 
Physical and Chemical Properties:
Molecular Formula C16H22O7S
Molecular Weight 358.40700
 
Specification:
Appearance:White crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Capecitabine(CAS:154361-50-9).



Contact us for information like ((3aR,4R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl 4-methylbenzenesulfonate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methyl 5-(4-methylbenzenesulfonate)-2,3-O-(1-methylethylidene)-D-ribofuranoside physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,methyl 5-(4-methylbenzenesulfonate)-2,3-O-(1-methylethylidene)-D-ribofuranoside Use and application,methyl 5-(4-methylbenzenesulfonate)-2,3-O-(1-methylethylidene)-D-ribofuranoside technical grade,usp/ep/jp grade.


Related News: As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials.3-((2-Mercapto-1-Methylpropyl)Thio)-2-Butanol manufacturer As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials.D-(+)-Methyl-alpha-(2-thienylethamino)(2-chlorophenyl)acetate hydrochloride supplier What are the symptoms? Coronavirus symptoms can look like the flu — fever, cough, trouble breathing. If you show these symptoms and recently went to China, or have been in contact with someone who visited, experts advise going to the doctor.4,4,5,5-tetramethyl-2-(4-(triphenylen-2-yl)phenyl)-1,3,2-dioxaborolane vendor With the structural upgrade of the pharmaceutical industry in developed countries, the transfer of related industrial chains has taken place globally, and it has also had a profound impact on Chinese pharmaceutical companies. nearThis dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?